$IMUX
Immunic Inc

2018 Q2 Form 10-Q Financial Statement

#000128077618000025 Filed on May 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2018 Q1 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.260M $4.340M $3.060M
YoY Change 56.62% 41.83% 9.29%
% of Gross Profit
Research & Development $2.157M $10.16M $9.628M
YoY Change -78.07% 5.49% 40.41%
% of Gross Profit
Depreciation & Amortization $200.0K $224.0K $335.0K
YoY Change -12.66% -33.13% -32.19%
% of Gross Profit
Operating Expenses $2.670M $2.288M $12.69M
YoY Change -78.72% -81.97% 31.39%
Operating Profit -$2.670M -$14.49M -$12.69M
YoY Change -78.72% 14.23% 31.39%
Interest Expense $160.0K $170.0K $100.0K
YoY Change -5.88% 70.0% 66.67%
% of Operating Profit
Other Income/Expense, Net $0.00 $104.0K $85.00K
YoY Change -100.0% 22.35% 26.87%
Pretax Income -$12.68M -$14.39M -$12.60M
YoY Change 2.18% 14.21% 31.39%
Income Tax
% Of Pretax Income
Net Earnings -$2.670M -$2.263M -$12.60M
YoY Change -78.48% -82.04% 31.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$11.96M -$13.58M -$15.37M
COMMON SHARES
Basic Shares Outstanding 42.37M shares 42.37M shares 32.14M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.10M $43.60M $86.60M
YoY Change -59.19% -49.65% 11.17%
Cash & Equivalents $31.12M $43.65M $86.64M
Short-Term Investments
Other Short-Term Assets $1.500M $1.200M $1.700M
YoY Change -21.05% -29.41% 30.77%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $32.65M $44.84M $88.30M
YoY Change -58.18% -49.23% 11.44%
LONG-TERM ASSETS
Property, Plant & Equipment $2.059M $2.072M $2.489M
YoY Change -15.27% -16.75% -27.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.00K $101.0K $156.0K
YoY Change -46.7% -35.26% -38.34%
Total Long-Term Assets $2.156M $2.173M $2.645M
YoY Change -17.46% -17.84% -28.14%
TOTAL ASSETS
Total Short-Term Assets $32.65M $44.84M $88.30M
Total Long-Term Assets $2.156M $2.173M $2.645M
Total Assets $34.80M $47.01M $90.95M
YoY Change -56.86% -48.31% 9.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.075M $893.0K $1.308M
YoY Change -0.09% -31.73% 47.8%
Accrued Expenses $7.185M $8.701M $5.085M
YoY Change 16.89% 71.11% 34.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.299M $9.666M $6.450M
YoY Change 13.81% 49.86% 33.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $100.0K
YoY Change -100.0% 0.0%
Total Long-Term Liabilities $49.00K $47.00K $69.00K
YoY Change 6.52% -31.88% 23.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.299M $9.666M $6.450M
Total Long-Term Liabilities $49.00K $47.00K $69.00K
Total Liabilities $8.348M $9.713M $6.519M
YoY Change 13.76% 49.0% 33.81%
SHAREHOLDERS EQUITY
Retained Earnings -$323.0M -$310.3M -$256.5M
YoY Change 20.13% 21.0% 20.73%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0% -92.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.97M -$15.57M $84.43M
YoY Change
Total Liabilities & Shareholders Equity $34.80M $47.01M $90.95M
YoY Change -56.86% -48.31% 9.68%

Cashflow Statement

Concept 2018 Q2 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$2.670M -$2.263M -$12.60M
YoY Change -78.48% -82.04% 31.42%
Depreciation, Depletion And Amortization $200.0K $224.0K $335.0K
YoY Change -12.66% -33.13% -32.19%
Cash From Operating Activities -$12.36M -$13.07M -$10.91M
YoY Change 21.77% 19.84% 9.54%
INVESTING ACTIVITIES
Capital Expenditures -$180.0K $150.0K $274.0K
YoY Change 28.57% -45.26% 119.2%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$180.0K -$150.0K -$270.0K
YoY Change 38.46% -44.44% -400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $37.50M
YoY Change -100.0% 767.05%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K -$30.00K 37.83M
YoY Change -104.76% -100.08% 773.67%
NET CHANGE
Cash From Operating Activities -12.36M -$13.07M -10.91M
Cash From Investing Activities -180.0K -$150.0K -270.0K
Cash From Financing Activities 10.00K -$30.00K 37.83M
Net Change In Cash -12.53M -$13.25M 26.65M
YoY Change 19.45% -149.73% -581.05%
FREE CASH FLOW
Cash From Operating Activities -$12.36M -$13.07M -$10.91M
Capital Expenditures -$180.0K $150.0K $274.0K
Free Cash Flow -$12.18M -$13.22M -$11.18M
YoY Change 21.68% 18.24% 10.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001280776
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42368998 shares
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
VITAL THERAPIES INC
CY2018Q1 dei Trading Symbol
TradingSymbol
VTL
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1049000 USD
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
893000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9141000 USD
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8701000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10323000 USD
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10547000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
78000 USD
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
75000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
345915000 USD
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
347557000 USD
CY2017Q4 us-gaap Assets
Assets
60384000 USD
CY2018Q1 us-gaap Assets
Assets
47008000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
58121000 USD
CY2018Q1 us-gaap Assets Current
AssetsCurrent
44835000 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
87000 USD
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59991000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86636000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56901000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43647000 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26645000 USD
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13254000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
92.99
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8299102 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368864 shares
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42368864 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368864 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42368864 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12601000 USD
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14391000 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
91000 USD
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
72000 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
59000 USD
CY2018Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
47000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
335000 USD
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
224000 USD
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3591000 USD
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1820000 USD
CY2018Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3059000 USD
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4335000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
396000 USD
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-145000 USD
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33000 USD
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-441000 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-17000 USD
CY2018Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-31000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
316000 USD
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-69000 USD
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
97000 USD
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
170000 USD
CY2017Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
89000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60384000 USD
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47008000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10281000 USD
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9666000 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
59000 USD
CY2018Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
47000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37826000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-30000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-271000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-150000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10910000 USD
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13074000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12602000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-14388000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85000 USD
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
12687000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
173000 USD
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
662000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
108000 USD
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000 USD
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
91000 USD
CY2018Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
72000 USD
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 USD
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000 USD
CY2017Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-2000 USD
CY2018Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-4000 USD
CY2017Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2018Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
30000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
274000 USD
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
14492000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12687000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14492000 USD
CY2017Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
255000 USD
CY2018Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
298000 USD
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
150000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1220000 USD
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1188000 USD
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37825000 USD
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2017Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
3000 USD
CY2018Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12478000 USD
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12619000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2155000 USD
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9628000 USD
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10157000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295953000 USD
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310341000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1263000 USD
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1553000 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3704451 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.92
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
11778 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.74
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1669104 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.48
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.40
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9639492 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6083482 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7740808 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.76
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9434249 USD
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7579288 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.68
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.31
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3152405 USD
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M22D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M6D
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y3M22D
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74700000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
50044000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
37295000 USD
CY2017 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2018Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 USD
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32645103 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42368864 shares
CY2017Q4 vtl Accrued Clinical Costs
AccruedClinicalCosts
5377000 USD
CY2018Q1 vtl Accrued Clinical Costs
AccruedClinicalCosts
6219000 USD
CY2017Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
481000 USD
CY2018Q1 vtl Common Stock Issuance Costs Included In Liabilities
CommonStockIssuanceCostsIncludedInLiabilities
0 USD
CY2018Q1 vtl Issuance Of Securities Authorized Offering Amount Under Shelf Registration
IssuanceOfSecuritiesAuthorizedOfferingAmountUnderShelfRegistration
112500000 USD
CY2015Q2 vtl Maximum Aggregate Offering Priceof Securities Under Shelf Registration
MaximumAggregateOfferingPriceofSecuritiesUnderShelfRegistration
200000000 USD
CY2015Q2 vtl Maximum Amount Of Common Stock That Can Be Issued Under At The Market Sales Agreement
MaximumAmountOfCommonStockThatCanBeIssuedUnderAtTheMarketSalesAgreement
75000000 USD
CY2015Q2 vtl Maximum Number Of Common Shares That Can Be Sold Under Shelf Registration Statement By Selling Shareholders
MaximumNumberOfCommonSharesThatCanBeSoldUnderShelfRegistrationStatementBySellingShareholders
2500000 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make certain estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001280776-18-000025-index-headers.html Edgar Link pending
0001280776-18-000025-index.html Edgar Link pending
0001280776-18-000025.txt Edgar Link pending
0001280776-18-000025-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtl-033118xexhibit311.htm Edgar Link pending
vtl-033118xexhibit312.htm Edgar Link pending
vtl-033118xexhibit321.htm Edgar Link pending
vtl-033118xexhibit322.htm Edgar Link pending
vtl-20180331.xml Edgar Link completed
vtl-20180331.xsd Edgar Link pending
vtl-20180331_cal.xml Edgar Link unprocessable
vtl-20180331_def.xml Edgar Link unprocessable
vtl-20180331_lab.xml Edgar Link unprocessable
vtl-20180331_pre.xml Edgar Link unprocessable
vtl-33118x10q.htm Edgar Link pending